Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Immunology Research
Cancer Immunology Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Monitoring the Immunological Response to Human Cancer

Immunological monitoring: Lessons from natural and vaccine-induced responses to Melan-A/MART-1

Jean-Charles Cerottini
Jean-Charles Cerottini
Ludwig Institute for Cancer Research Lausanne, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published January 2003
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

It is widely accepted that cancer immunotherapy will be most effective in patients with early disease or minimal residual disease. The initial evaluation of various vaccine-based strategies in such patients cannot rely on usual clinical end points, such as tumor regression or time to recurrence, because of the number of patients and years required to achieve meaningful results. Following the identification of T cell-defined tumor antigens, it has been proposed to use immunologic assays that enable quantitative and qualitative monitoring of antigen-specific T-cell responses for the evaluation of new immunotherapeutic strategies in phase I clinical trials. Recent advances in immunological monitoring now allows direct detection and functional characterization of antigen-specific T cells. In particular, the use of soluble, fluorescently labeled HLA class I/peptide complexes, commonly referred to as tetramers or multimers, allows direct enumeration by flow cytometry of antigen-specific CD8+ T cells provided their frequencies are >1 in 10,000 cells. Moreover, by combining tetramers with appropriate antibodies, it is possible to obtain a direct assessment of the surface and functional phenotype of antigen-specific CD8+ T cells at the single cell level. Finally, following tetramer-based cell sorting of antigen-specific CD8+ T cells, further characterization, including T-cell receptor usage, functional potential and assessment of proliferative history, can be carried out in the absence of irrelevant cells.

In the past few years, our laboratory has applied these assays to assess the number as well as the quality of CD8+ T cells directed against the melanocyte/melanoma differentiation antigen Melan-A/MART-1 in HLA-A2 positive melanoma patients before and after peptide-based vaccination. In contrast to other tumor antigens, Melan-A has two features that makes this antigen a unique model to monitor antigen-specific T-cell responses: (i) it contains a single immunodominant peptide presented by HLA-A2, and (ii) the majority of HLA-A2 healthy individuals exhibit a relatively high number (up to 1 in 1,000 cells) of circulating CD8+ T cells that stain specifically with HLA-A2/Melan peptide multimers. Remarkably, this high frequency is not generated through peripheral T cell expansion, but reflects the thymic output of a high number of specific T cells that are maintained in a naïve state throughout life. In contrast, although the mean frequency of Melan-A multimer+ T cells in peripheral blood of HLA-A2 melanoma patients is not significantly different from that found in healthy individuals, a distinct, albeit variable, proportion of these cells display an activated/memory phenotype. In addition, in such patients, the frequency of Melan-A multimer+ T cells in metastatic lymph nodes is very high (up to 1 in 10 CD8+ T cells) and close to 100% of these cells exhibit an activated/memory phenotype, thus demonstrating that strong tumor antigen-specific responses may naturally occur in cancer patients.

Based on these findings, we have recently applied the assays mentioned above to the longitudinal analysis of Melan-A specific CD8+ T cells in melanoma patients enrolled in Melan-A peptide-based vaccine trials. The contrasting results obtained in two patients, which illustrate the usefulness of incorporating detailed immunological monitoring in clinical trials of antigen-specific immunotherapy, will be discussed.

This abstract was published in Cancer Immunity, a Cancer Research Institute journal that ceased publication in 2013 and is now provided online in association with Cancer Immunology Research.

 

  • Copyright © 2003 by Jean-Charles Cerottini

References

  1. 1.
    1. Zippelius A,
    2. Pittet MJ,
    3. Batard P,
    4. Rufer N,
    5. de Smedt M,
    6. Guillaume P,
    7. Ellefsen K,
    8. Valmori D,
    9. Lienard D,
    10. Plum J,
    11. MacDonald HR,
    12. Speiser DE,
    13. Cerottini JC,
    14. Romero P
    . Thymic selection generates a large T cell pool recognizing a self-peptide in humans. J Exp Med 2002;195:485–94.pmid:11854361
    OpenUrlAbstract/FREE Full Text
  2. 2.
    1. Speiser DE,
    2. Lienard D,
    3. Pittet MJ,
    4. Batard P,
    5. Rimoldi D,
    6. Guillaume P,
    7. Cerottini JC,
    8. Romero P
    . In vivo activation of melanoma-specific CD8+ T cells by endogenous tumor antigen and peptide vaccines. A comparison to virus-specific T cells. Eur J Immunol 2002;32:731–41.pmid:11870617
    OpenUrlCrossRefPubMed
  3. 3.
    1. Valmori D,
    2. Dutoit V,
    3. Schnuriger V,
    4. Quiquerez AL,
    5. Pittet MJ,
    6. Guillaume P,
    7. Rubio-Godoy V,
    8. Walker PR,
    9. Rimoldi D,
    10. Lienard D,
    11. Cerottini JC,
    12. Romero P,
    13. Dietrich PY
    . Vaccination with a Melan-A peptide selects an oligoclonal T cell population with increased functional avidity and tumor reactivity. J Immunol 2002;168:4231–40.pmid:11937585
    OpenUrlAbstract/FREE Full Text
  4. 4.
    1. Pittet MJ,
    2. Zippelius A,
    3. Valmori D,
    4. Speiser DE,
    5. Cerottini JC,
    6. Romero P
    . Melan-A/MART-1-specific CD8 T cells: from thymus to tumor. Trends Immunol 2002;23:325–8.pmid:12103339
    OpenUrlCrossRefPubMed
  5. 5.
    1. Romero P,
    2. Valmori D,
    3. Pittet MJ,
    4. Zippelius A,
    5. Rimoldi D,
    6. Lévy F,
    7. Dutoit V,
    8. Rubio-Godoy V,
    9. Michielin O,
    10. Guillaume P,
    11. Batard P,
    12. Luescher IF,
    13. Lejeune F,
    14. Liénard D,
    15. Rufer N,
    16. Dietrich PY,
    17. Speiser DE,
    18. Cerottini JC
    . Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma. Immunol Rev 2002;188:81–96.pmid:12445283
    OpenUrlCrossRefPubMed
View Abstract
PreviousNext
Back to top
Cancer Immunity Archive: 3 (Suppl 1)
January 2003
Volume 3, Issue Suppl 1
  • Table of Contents

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Immunology Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Immunological monitoring: Lessons from natural and vaccine-induced responses to Melan-A/MART-1
(Your Name) has forwarded a page to you from Cancer Immunology Research
(Your Name) thought you would be interested in this article in Cancer Immunology Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Immunological monitoring: Lessons from natural and vaccine-induced responses to Melan-A/MART-1
Jean-Charles Cerottini
Cancer Immun January 1 2003 (3) (Suppl 1) 11;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Immunological monitoring: Lessons from natural and vaccine-induced responses to Melan-A/MART-1
Jean-Charles Cerottini
Cancer Immun January 1 2003 (3) (Suppl 1) 11;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • References
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Monitoring of immune responses against NY-ESO-1 in cancer patients
  • Comprehensive approaches to monitor CD8+ T-cell responses against tumor antigen NY-ESO-1
Show more Monitoring the Immunological Response to Human Cancer
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Cancer Immunology Essentials

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Immunology Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Immunology Research
eISSN: 2326-6074
ISSN: 2326-6066

Advertisement